Literature DB >> 22483956

Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.

Odile Picard1, Patrice Cacoub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22483956     DOI： 10.1016/j.clinre.2012.02.004

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN： 2210-7401            Impact factor:   2.947


× No keyword cloud information.
  6 in total

1.  Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.

Authors:  Elżbieta Kłujszo; Piotr Parcheta; Dorota Zarębska-Michaluk; Ewa Ochwanowska; Anna Witkowska; Adriana Rakowska; Lidia Rudnicka; Wiesław Kryczka
Journal:  J Dermatol Case Rep       Date:  2014-12-31

2.  Telaprevir to boceprevir switch highlights lack of cross-reactivity.

Authors:  Amanda Carlson; Zachery Gregorich; Rob Striker
Journal:  Clin Infect Dis       Date:  2012-11-19       Impact factor: 9.079

3.  Grade 4 febrile neutropenia and Fournier's Syndrome associated with triple therapy for hepatitis C virus: A case report.

Authors:  Kelly Cristhian Lima Oliveira; Emili de Oliveira Bortolon Cardoso; Suzana Carla Pereira de Souza; Flávia Souza Machado; Carlos Eduardo Alves Zangirolami; Alecsandro Moreira; Giovanni Faria Silva; Cássio Vieira de Oliveira
Journal:  World J Hepatol       Date:  2014-06-27

4.  Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience.

Authors:  Thalia Medeiros; Camila de Morais Salviato; Natalia Fonseca do Rosário; Geórgia do Nascimento Saraiva; Eliane Bordalo Cathalá Esberard; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice da Silva
Journal:  Int J Clin Pharm       Date:  2017-10-27

5.  Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis.

Authors:  Alessandro Federico; Dolores Sgambato; Gaetano Cotticelli; Antonietta Gerarda Gravina; Marcello Dallio; Filippo Beneduce; Eleonora Ruocco; Marco Romano; Carmela Loguercio
Journal:  Hepat Mon       Date:  2014-03-11       Impact factor: 0.660

6.  Cutaneous Eruption due to Telaprevir.

Authors:  Eduardo Mastrangelo Marinho Falcão; Beatriz Moritz Trope; Mariana Marteleto Godinho; Leonardo Hoehl Carneiro; João Marcello de Araujo-Neto; Cristiane Alves Villela Nogueira; Marcia Ramos-E-Silva
Journal:  Case Rep Dermatol       Date:  2015-09-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.